An observational study in Necrotising Enterocolitis Neonatal, sponsored by Ankara Yildirim Beyazıt University. Completed at 1 site in Turkey. Open to participants aged 3 Days to 30 Days. Per ClinicalTrials.gov, last updated 2024-11-18.
Sponsored by Ankara Yildirim Beyazıt University · Observational
Necrotizing enterocolitis (NEC) is a serious condition that can affect premature babies, leading to complications like intestinal damage and infection. In our study, we measured specific markers (called calprotectin) in blood and stool to understand how severe NEC is and predict outcomes. We found that these markers were higher in babies with more severe NEC (stage 3), especially in those who needed surgery or sadly did not survive. This information can help doctors detect NEC earlier, understand its severity, and make better decisions for treating affected babies.
228 studies on the registry are indexed under Enterocolitis, Necrotizing; 44 are open to participants now.
This study's enrollment of 59 is below the median of 144 across 95 observational studies indexed under Enterocolitis, Necrotizing.
Browse Enterocolitis, Necrotizing studies →Ankara Yildirim Beyazıt University is the lead sponsor of 241 studies on the registry; 54 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Newborns admitted to the neonatal intensive care unit (NICU) over a 2-year period, born at or before 32 weeks of gestation with a birth weight of ≤1500 grams, were included in this study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
before 32 weeks of gestation with a birth weight of ≤1500 grams
Exclusion Criteria:
Infants whose families did not provide consent and those with congenital anomalies were excluded.
The predictive value of serum and fecal calprotectin levels in necrotising enterocolitis (NEC)
The predictive value of serum and fecal calprotectin levels in assessing NEC severity (stage 2 and stage 3), intestinal perforation, the need for surgery, and mortality.
Time frame: 2 years
Plan to share: Yes
Supporting information: Study protocol
Time frame: The IPD and supporting information will be available starting 6 months after the publication of the study results and will remain one year.
Access criteria: Access to IPD and supporting information will be available to qualified researchers affiliated with academic or medical institutions. They will be able to access study protocol through a formal data-sharing agreement. Requests must be submitted via email to [sarasurmeli@gmail.com]
No publications or documents are linked to this record.
Ran from Jun 2022 to primary completion in Jan 2024, 19 months.
Of 39 observational studies under Enterocolitis, Necrotizing, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 115. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Ankara Yildirim Beyazıt University →